S&P 500US$7,674.37+0.43%NASDAQUS$26,180.46+0.43%DOWUS$53,277.01+0.98%DAX€26,137.59+0.00%FTSE 100£10,821.52+0.05%NIKKEI 225JP¥65,528.09-0.74%VIXUS$15.87+4.89%BTCUS$78,561.00+1.95%ETHUS$2,493.92+2.92%

News Archive

Every report the desk has filed, searchable by full text, topic, format, symbol and date range.

Filtering:FDMT

Biotech Coverage Wave: H.C. Wainwright Reaffirms Buys Across Pharvaris, 4D Molecular, Cytokinetics and CorMedix

A concentrated round of reiterations tied to regulatory milestones, patent litigation and quarterly execution underscores that small-cap biotech is being underwritten on catalysts rather than sector beta.

H.C. Wainwright reiterated constructive ratings on four clinical and commercial-stage biotechs on the same session, citing regulatory progress at Pharvaris, a $36 target on 4D Molecular, patent-suit developments at Cytokinetics and a strong quarter at CorMedix.

BREAKING STORYBULLISH14 Aug 2026

Regulation Healthcare & PharmaPHVS FDMT CYTK CRMDRead report →

Most covered symbols

GSPC NVDA TNX GOOGL BTC-USD IXIC MU AAPL CL=F TLT AMD BABA COIN CRWV GLD META MSFT NDX 000660.KS MSTR NBIS TSLA RKLB SNDK STOXX STOXX50E AMZN AVGO BRK.B BTC PLTR SMCI WMT XOM N225 BRK.A BZ=F DX-Y.NYB GC=F HOOD

Each chip opens the Research terminal for that symbol, where its archive coverage is listed alongside the fundamentals.